Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
initial presentation
secure airway
No action should be taken that could stimulate a child with suspected epiglottitis. Epiglottitis is a clinical diagnosis and laboratory or other interventions should not preclude or delay timely control of the airway if epiglottitis is suspected. This includes examination of the oral cavity, starting intravenous lines, blood draws, or even separation of a child from a parent. Similar caution is required in fulminant acute epiglottitis in adults. The patient should be kept in an upright position as supine positioning can aggravate airway obstruction.[23]Lindquist B, Zachariah S, Kulkarni A. Adult Epiglottitis: a case series. Perm J. 2017;21:16-089. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283781 http://www.ncbi.nlm.nih.gov/pubmed/28241903?tool=bestpractice.com
Direct rigid laryngoscopy and intubation are most commonly performed. Flexible fiber-optic examination should only be performed with great caution in adults only.
The treatment chosen will be dictated by the patient's clinical situation and the facility's capabilities. Mask ventilation followed by intubation is often the first choice.
Adult patients may have a more indolent presentation, and may not always require airway intervention (only about 10% of adults require airway intervention whereas most children do).[4]Wong EY, Berkowitz RG. Acute epiglottitis in adults: the Royal Melbourne Hospital experience. ANZ J Surg. 2001 Dec;71(12):740-3. http://www.ncbi.nlm.nih.gov/pubmed/11906390?tool=bestpractice.com [24]Booth AWG, Pungsornruk K, Llewellyn S, et al. Airway management of adult epiglottitis: a systematic review and meta-analysis. BJA Open. 2024 Mar;9:100250. https://www.bjaopen.org/article/S2772-6096(23)00129-6/fulltext http://www.ncbi.nlm.nih.gov/pubmed/38230383?tool=bestpractice.com Unnecessary airway intervention in adults may increase morbidity and mortality, given the relatively high intubation failure rate of one in 25.[24]Booth AWG, Pungsornruk K, Llewellyn S, et al. Airway management of adult epiglottitis: a systematic review and meta-analysis. BJA Open. 2024 Mar;9:100250. https://www.bjaopen.org/article/S2772-6096(23)00129-6/fulltext http://www.ncbi.nlm.nih.gov/pubmed/38230383?tool=bestpractice.com However, adults may be at risk for airway obstruction and sudden decline due to supraglottic inflammation and edema. They should be transferred to ICU level care (with the ability to perform airway intervention) for ventilatory management if they are intubated, or for observation if not intubated in case of deterioration.[25]Bridwell RE, Koyfman A, Long B. High risk and low prevalence diseases: Adult epiglottitis. Am J Emerg Med. 2022 Jul;57:14-20. http://www.ncbi.nlm.nih.gov/pubmed/35489220?tool=bestpractice.com [26]Pineau PM, Gautier J, Pineau A, et al. Intubation decision criteria in adult epiglottitis. Eur Ann Otorhinolaryngol Head Neck Dis. 2021 Oct;138(5):329-32. https://www.sciencedirect.com/science/article/pii/S1879729620302842?via%3Dihub http://www.ncbi.nlm.nih.gov/pubmed/33358682?tool=bestpractice.com
Tracheotomy/cricothyroidotomy may be performed in an emergency in patients who cannot be safely intubated.
Rarely, a patient will fail the initial extubation trial or the airway may not be ready for extubation after 72 hours and prolonged intubation until the patient meets criteria may be warranted.
intravenous antibiotics
Treatment recommended for ALL patients in selected patient group
Antibiotics are advocated as empiric therapy and their use will depend on susceptibility of cultures taken.[1]Flint PW, Haughey BH, Lund VJ, et al. Cummings otolaryngology: head and neck surgery. 7th ed. Elsevier; 2020.[27]McEwan J, Giridharan W, Clarke RW. Paediatric acute epiglottitis: not a disappearing entity. Int J Pediatr Otorhinolaryngol. 2003 Apr;67(4):317-21. http://www.ncbi.nlm.nih.gov/pubmed/12663101?tool=bestpractice.com Vancomycin or clindamycin may be used in patients who are allergic to penicillin.[28]Dowdy RAE, Cornelius BW. Medical management of epiglottitis. Anesth Prog. 2020 Jun 1;67(2):90-7. http://www.ncbi.nlm.nih.gov/pubmed/32633776?tool=bestpractice.com
Institutions often have their own regimens of antibiotics, depending on local resistance. An infectious disease physician can be consulted and local guidelines followed for proper antimicrobial coverage because combination antibiotic therapy is a potential consideration in a patient with epiglottitis. Until culture-driven therapy is possible, broad-spectrum coverage may be recommended to include Haemophilus influenzae and Staphylococcus aureus.
Primary options
cefotaxime: children: 150-200 mg/kg/day intravenously given in divided doses every 6-8 hours; adults: 1-2 g intravenously every 6-12 hours; maximum 12 g/day
OR
ceftriaxone: children with mild to moderate infections: 50-75 mg/kg/day intravenously given in divided doses every 12-24 hours; children with severe infections: 80-100 mg/kg/day intravenously given in divided doses every 12-24 hours; adults: 1-2 g intravenously given in divided doses every 12-24 hours; maximum 4 g/day
OR
ampicillin/sulbactam: children: 100-200 mg/kg/day intravenously given in divided doses every 6 hours; adults: 1.5 to 3 g intravenously every 6 hours; maximum 12 g/day
OR
oxacillin: children: 200 mg/kg/day intravenously given in divided doses every 6 hours; adults: 2 g intravenously every 6 hours; maximum 12 g/day
OR
nafcillin: children: 100 mg/kg/day intravenously given in divided doses every 6 hours; adults: 2 g intravenously every 6 hours; maximum 12 g/day
OR
clindamycin: children: 15-25 mg/kg/day intravenously given in divided doses every 6 hours; adults: 600 mg intravenously every 6 hours
OR
vancomycin: children: 40 mg/kg/day intravenously given in divided doses every 6-8 hours; adults: 2 g/day intravenously given in divided doses every 6-12 hours
-- AND --
cefotaxime: children: 150-200 mg/kg/day intravenously given in divided doses every 6-8 hours; adults: 1-2 g intravenously every 6-12 hours; maximum 12 g/day
or
ceftriaxone: children with mild to moderate infections: 50-75 mg/kg/day intravenously given in divided doses every 12-24 hours; children with severe infections: 80-100 mg/kg/day intravenously given in divided doses every 12-24 hours; adults: 1-2 g intravenously given in divided doses every 12-24 hours; maximum 4 g/day
supplemental oxygen
Treatment recommended for SOME patients in selected patient group
Supplemental oxygen and possibly heliox may be used as a temporizing measure. This is a viable option in a stable patient without signs of impending airway compromise.
corticosteroids
Treatment recommended for SOME patients in selected patient group
While not proven in controlled trials, corticosteroids may be used to reduce supraglottic inflammation per clinician discretion.[9]Guardiani E, Bliss M, Harley E. Supraglottitis in the era following widespread immunization against Haemophilus influenzae type B: evolving principles in diagnosis and management. Laryngoscope. 2010 Nov;120(11):2183-8. http://www.ncbi.nlm.nih.gov/pubmed/20925091?tool=bestpractice.com
Primary options
dexamethasone: children: 0.08 to 0.3 mg/kg/day orally given in divided doses every 6-12 hours; adults: 0.75 to 9 mg/day orally given in divided doses every 6-12 hours according to response
once stable and extubated
oral antibiotics
Once the patient is not intubated and tolerating orals, further antibiotics can be given to be taken at home.
Primary options
amoxicillin/clavulanate: children: 25-45 mg/kg/day orally given in divided doses every 12 hours; adults: 500-875 mg orally every 12 hours
More amoxicillin/clavulanateSuitable for gram-positive cultures.
Dose refers to amoxicillin component.
OR
cefaclor: children: 20-40 mg/kg/day orally given in divided doses every 8-12 hours; adults: 250-500 mg orally every 8 hours
More cefaclorSuitable for gram-negative cultures.
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer